Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

venous thromboembolism

- PMLiVE

Janssen submits blood cancer drug in EU

Seeks EMA approval for ibrutinib

- PMLiVE

Buoyant pharma sales drive J&J’s Q3 results

Defies downturn with European growth of 12 per cent

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

- PMLiVE

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

- PMLiVE

Bayer gets US nod for first-in-class Adempas

FDA clears drug for use in pulmonary artery hypertension

- PMLiVE

European R&D investment “stagnating”

Report says health research spend was flat in 2011

Bayer symbol

Bayer expects five drugs to enter phase III in 2015

Hopes to follow success of recent launches

- PMLiVE

Pfizer’s Brandicourt joins Bayer Healthcare as CEO

He replaces acting chief executive Wolfgang Plischke

National Institute for Health and Care Excellence NICE logo

NICE to update ovarian cancer drug guidelines

Draft guidance backs paclitaxel and Janssen’s Caelyx but not gemcitabine, topetecan or trabectedin

- PMLiVE

Janssen expands its ‘mobile health manager’

Add family support option to adherence campaign

Roche - Basel

Roche’s Kadcyla and Bayer’s Xofigo near EU approval

Cancer drugs receive CHMP backing

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links